Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers World Congress 2018

J. Carl Barrett's Biography



J. Carl Barrett, Vice President, Translational Sciences Oncology, AstraZeneca

Dr. J. Carl Barrett is Vice President of Translational Science in Oncology at AstraZeneca. He is responsible for development and execution of biomarker strategies and translational sciences efforts to support compound development from research through early and full development in oncology. From 2005-2011, he was Global Head of Oncology Biomarkers and Imaging at Novartis.

Dr. Barrett was the founding Director of the NCI Center for Cancer Research (CCR), the NCI intramural center for translation medicine. He was also Scientific Director at the National Institute of Environmental Health Sciences where he focused on integrating new approaches to toxicogenomics, molecular toxicology, and the Environmental Genome Project.

Dr. Barrett’s research focused on the discovery of the critical genetic and epigenetic changes in the cancer cell, in particular the discovery of genes involved in breast cancer (BRCA1). Trained as a chemist at the College of William and Mary, he received his Ph.D. degree in Biophysical Chemistry from Johns Hopkins University. He has published over 600 research articles. He is a member of the Johns Hopkins University Society of Scholars, the Ramazini Foundation, an honorary member of the Japanese Cancer Association, and a recipient of multiple NIH awards and Keynote lectures.

J. Carl Barrett Image

Utility and Challenges of ctDNA

Wednesday, 28 March 2018 at 17:00

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

ctDNA is rapidly becoming a major clinical tool for identifying patients for therapy, monitoring response of therapy and exploring mechanisms of resistance to therapies. Examples of all these applications will be presented. It is imperative that ctDNA assay are sensitive and specific. Data on the performance of different assays will be presented as well the basis for lack of concordance in certain situations.

Utility and Challenges of ctDNA

Wednesday, 28 March 2018 at 17:00

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

ctDNA is rapidly becoming a major clinical tool for identifying patients for therapy, monitoring response of therapy and exploring mechanisms of resistance to therapies. Examples of all these applications will be presented. It is imperative that ctDNA assay are sensitive and specific. Data on the performance of different assays will be presented as well the basis for lack of concordance in certain situations.


Add to Calendar ▼2018-03-28 00:00:002018-03-29 00:00:00Europe/LondonCirculating Biomarkers World Congress 2018Circulating Biomarkers World Congress 2018 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com